Clinical observation on the treatment efficacy of Cyberknife for iliac lymph node metastasis / 中华放射医学与防护杂志
Chinese Journal of Radiological Medicine and Protection
; (12): 278-281, 2017.
Article
em Zh
| WPRIM
| ID: wpr-512100
Biblioteca responsável:
WPRO
ABSTRACT
Objective To evaluate the response rate and efficacy of Cyberknife in the treatment of iliac lymph node metastases (ILNM).Methods Twenty-two patients with 27 ILNM were treated by Cyberknife from May 2010 to May 2016.Tumor volume range from 0.88 to 125.66 cm3 (median 18.87 cm3).The total doses ranged from 21 to 51 Gy (median 39 Gy) and biological effective doses from 35.7 to 100 Gy (median 72.6 Gy) in 3-8 fractions (median 5).Sixty-four percent to eighty-two percent (median 72%) isodose line covered planning target.The survival rates were calculated by Kaplan-Meier method and compared with Log-rank test.Results Follow-up time ranged from 8 to 97 months (median 33 months).The complete response,partial response,stable disease and progression disease rates were 37%,48%,7.5%,48%,respectively.In addition,effective rate was 92.5%.Overall survival range from 4 to 68 months (median 21 months).The 1-,2-,3-year local control rate was all 90.6% and the survival rates were 78.8%,60.6% and 43.3%,respectively.Adverse reactions after treatment were gastrointestinal reactions such as nausea,vomiting,fatigue.The chemotherapy before Cyberknife helped to improve overall survival.The patients with backache or edema of lower extremity got rapid relief after treatment.Conclusion The treatment of ILNM with Cyberknife has provided a high response rate with minimal side effects.Cyberknife is a safe and effective local treatment method for ILNM.
Texto completo:
1
Índice:
WPRIM
Idioma:
Zh
Revista:
Chinese Journal of Radiological Medicine and Protection
Ano de publicação:
2017
Tipo de documento:
Article